IMGN - ImmunoGen, Inc.
| Previous Close | 9.97 |
| Open | 10.00 |
| Bid | 9.95 x 200 |
| Ask | 10.89 x 100 |
| Day's Range | 9.95 - 10.37 |
| 52 Week Range | 4.80 - 13.41 |
| Volume | 2,763,172 |
| Avg. Volume | 2,743,115 |
| Market Cap | 1.525B |
| Beta | 3.59 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.08 |
| Earnings Date | Jul 27, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 14.50 |
- Motley Fool•8 days ago
Here's Why ImmunoGen Fell 15.1% in June
A secondary offering dilutes investors.
- Business Wire•9 days ago
ImmunoGen Announces Conference Call to Discuss Its Second Quarter 2018 Operating Results
ImmunoGen, Inc., (IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Company will host a conference call at 8:00 a.m. ET on Friday, July 27, 2018 to discuss its second quarter operating results. The call may also be accessed through the Investors section of the Company’s website, www.immunogen.com. ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients.
- Motley Fool•25 days ago
Better Buy: Exelixis, Inc. vs. Immunogen, Inc.
Which of these cancer-focused biotech stocks is the better pick right now?
- ACCESSWIRE•29 days ago
Free Technical Research on ImmunoGen and Three More Biotech Equities
On Thursday, June 21, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged lower at the closing bell. Eight out of nine sectors ended Thursday's trading session in bearish territories. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Biotechnology equities this morning: Grifols S.A. (NASDAQ: GRFS), Halozyme Therapeutics Inc. (NASDAQ: HALO), ImmunoCellular Therapeutics Ltd (NYSE AMER: IMUC), and ImmunoGen Inc. (NASDAQ: IMGN).
- Business Wire•last month
ImmunoGen Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares
ImmunoGen, Inc. (IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the underwriters of its previously announced public offering of common stock have exercised in full their option to purchase an additional 2,055,000 shares of ImmunoGen’s common stock at a price of $11.00 per share, before underwriting discounts. The exercise of the option brings the total shares of common stock to be sold by ImmunoGen in the offering to 15,755,000 shares. All of the shares in the offering are to be sold by ImmunoGen.
- Zacks•last month
ImmunoGen's Lead Candidate Gets Fast Track for Ovarian Cancer
With ImmunoGen's (IMGN) lead pipeline candidate, mirvetuximab soravtansine getting Fast Track designation in the United States, its development and review are likely to get expedited.
- Business Wire•last month
ImmunoGen Announces FDA Fast Track Designation for Mirvetuximab Soravtansine in Patients with Platinum-Resistant Ovarian Cancer
ImmunoGen, Inc. (IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its lead program, mirvetuximab soravtansine. The designation is for the treatment of patients with medium to high folate receptor alpha (FRα)-positive platinum-resistant ovarian cancer who received at least one, but no more than three prior systemic treatment regimens, and for whom single-agent chemotherapy is appropriate as the next line of therapy. “We are pleased the FDA has granted Fast Track designation for mirvetuximab soravtansine,” said Mark Enyedy, ImmunoGen’s President and Chief Executive Officer.
- Business Wire•last month
ImmunoGen Announces Closing of Public Offering of Common Stock
ImmunoGen, Inc. (IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the closing of its previously announced underwritten public offering of 13,700,000 shares of its common stock at a price to the public of $11.00 per share. The gross proceeds to ImmunoGen from the offering (before deducting the underwriting discounts and offering expenses) were $150.7 million. In addition, ImmunoGen has granted the underwriters a 30-day option to purchase up to an additional 2,055,000 shares of common stock at the public offering price, less the underwriting discount.
- Motley Fool•last month
Here's Why ImmunoGen Inc. Fell 9.2% Today
A secondary offering will dilute investors.
- Business Wire•last month
ImmunoGen Announces Pricing of Upsized Public Offering of Common Stock
ImmunoGen, Inc. (IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the pricing of an upsized underwritten public offering of 13,700,000 shares of its common stock at a price of $11.00 per share, before underwriting discounts. In addition, ImmunoGen has granted the underwriters a 30-day option to purchase up to an additional 2,055,000 shares of common stock at the public offering price, less the underwriting discount. The offering was upsized from the previously announced offering size of 12,000,000 shares of common stock.
- Benzinga•last month
Benzinga's Daily Biotech Pulse: Vascular Biogenics Soars On Positive Platform Data, Axovant Licenses Parkinson's Candidate
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on June 5) Haemonetics Corporation (NYSE: HAE ) Athersys, Inc. (NASDAQ: ...
- Simply Wall St.•last month
Has ImmunoGen Inc (NASDAQ:IMGN) Improved Earnings Growth In Recent Times?
Understanding ImmunoGen Inc’s (NASDAQ:IMGN) performance as a company requires examining more than earnings from one point in time. Today I will take you through a basic sense check to gainRead More...
- MarketWatch•2 months ago
Immunogen shares down 4% after company's plans for secondary offering
Shares of Immunogen Inc. fell more than 4% late Tuesday after the biotech company said it plans to offer and sell 12 million shares of its common stock in a public offering. J.P. Morgan Securities, Goldman Sachs, and Cowen and Co. are joint book-runners. Shares of Immunogen ended the regular trading session up 7.4%.
- Business Wire•2 months ago
ImmunoGen Announces Proposed Public Offering of Common Stock
ImmunoGen, Inc. (IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that it intends to offer and sell, subject to market and other conditions, 12,000,000 shares of its common stock in an underwritten public offering. ImmunoGen also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the public offering. All of the shares of common stock to be sold in the offering are to be offered by ImmunoGen.
- Zacks•2 months ago
Why Is ImmunoGen (IMGN) Up 4.2% Since Its Last Earnings Report?
ImmunoGen (IMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Motley Fool•2 months ago
Why ImmunoGen Jumped Higher Today
Investors are looking forward to the biotech's presentation at ASCO.
- Business Wire•2 months ago
ImmunoGen Announces Webcast of Presentation at Jefferies 2018 Global Healthcare Conference
ImmunoGen, Inc. (IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will present at the upcoming Jefferies 2018 Global Healthcare Conference. ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients.
- Business Wire•2 months ago
ImmunoGen Announces Positive Findings from the FORWARD II Study of Mirvetuximab Soravtansine Combination Regimens with Avastin® and Carboplatin in Ovarian Cancer
ImmunoGen, Inc., , a leader in the expanding field of antibody-drug conjugates for the treatment of cancer today announced positive data from the FORWARD II trial evaluating mirvetuximab soravtansine in multiple combination cohorts in patients with folate receptor alpha -positive ovarian cancer.
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of IMGN earnings conference call or presentation 4-May-18 12:00pm GMT
Q1 2018 ImmunoGen Inc Earnings Call
- Motley Fool•2 months ago
ImmunoGen Presses Forward
The biotech waits for clinical trial results for its lead drug, mirvetuximab.
- Zacks•2 months ago
ImmunoGen (IMGN) Q1 Loss Wider Than Expected, Revenues Beat
ImmunoGen (IMGN) reports wider-than-expected loss in Q1. Lower license and milestone fees resulted in substantial decrease in year-over-revenues.
- Zacks•3 months ago
ImmunoGen (IMGN) Q1 Loss Wider, Revenues Beat
ImmunoGen posted wider-than-expected loss in the first quarter of 2018. However, revenues surpassed estimates but decreased year over year.
- Associated Press•3 months ago
ImmunoGen: 1Q Earnings Snapshot
On a per-share basis, the Waltham, Massachusetts-based company said it had a loss of 30 cents. The results missed Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment ...
- Business Wire•3 months ago
ImmunoGen Reports Recent Progress and First Quarter 2018 Operating Results
ImmunoGen, Inc. , a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, today reviewed recent progress in the business and reported operating results for the quarter ended March 31, 2018.
- ACCESSWIRE•3 months ago
ImmunoGen, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / May 4, 2018 / ImmunoGen, Inc. (NASDAQ: IMGN ) will be discussing their earnings results in their Q1 Earnings Call to be held on May 4, 2018 at 8:00 AM Eastern Time. To listen ...
